BiotechTube

ONO-5920

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Involutional Osteoporosis

Conditions

Involutional Osteoporosis

Trial Timeline

May 1, 2003 → —

NCT ID
NCT00212719

About ONO-5920

ONO-5920 is a phase 3 stage product being developed by Ono Pharmaceutical for Involutional Osteoporosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00212719. Target conditions include Involutional Osteoporosis.

What happened to similar drugs?

0 of 2 similar drugs in Involutional Osteoporosis were approved

Approved (0) Terminated (0) Active (2)
🔄ONO-5920Astellas PharmaPhase 3
🔄Minodronic acid hydrateAstellas PharmaPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00212719Phase 3Completed

Competing Products

2 competing products in Involutional Osteoporosis

See all competitors
ProductCompanyStageHype Score
ONO-5920Astellas PharmaPhase 3
40
Minodronic acid hydrateAstellas PharmaPhase 3
40